Multiple Sclerosis Research Today is a free monthly online journal that collates and summarizes the latest research about Multiple Sclerosis, including details on diagnosis, symptoms, treatment, prognosis.

Volume 4 (2007), Issue 3 (March)

1. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis.
   J Neurosci, 27(9): 2396-402. [Abstract] [Full-text]
2. The immunodominant CD8+ T cell epitope region of Theiler's virus in resistant C57BL/6 mice is critical for anti-viral immune responses, viral persistence, and binding to the host cells.
   Virology, 360(1): 159-71. [Abstract] [Full-text]
3. Age at onset determines the occurrence of the progressive phase of multiple sclerosis.
   Neurology, 68(10): 779-81. [Abstract] [Full-text]
4. Gray and normal-appearing white matter in multiple sclerosis: an MRI perspective.
   Expert Rev Neurother, 7(3): 271-9. [Abstract] [Full-text]
5. Interferon-beta1b in multiple sclerosis.
   Expert Rev Neurother, 7(3): 227-39. [Abstract] [Full-text]
6. Cross-diagnostic validity of the SF-36 physical functioning scale in patients with stroke, multiple sclerosis and amyotrophic lateral sclerosis: a study using Rasch analysis.
   J Rehabil Med, 39(2): 163-9. [Abstract] [Full-text]
7. Progressive impairment of autonomic control of heart rate in patients with multiple sclerosis.
   Arch Med Res, 38(3): 322-5. [Abstract] [Full-text]
8. High CSF neurofilament heavy chain levels in neuromyelitis optica.
   Neurology, 68(11): 865-7. [Abstract] [Full-text]
9. Quantitative MRI-pathology correlations of brain white matter lesions developing in a non-human primate model of multiple sclerosis.
   NMR Biomed, 20(2): 90-103. [Abstract] [Full-text]
10. Progression of non-age-related callosal brain atrophy in multiple sclerosis: a 9-year longitudinal MRI study representing four decades of disease development.
    J Neurol Neurosurg Psychiatry, 78(4): 375-80. [Abstract] [Full-text]
11. Childhood-onset multiple sclerosis: report of 82 patients from Isfahan, Iran.
    Arch Iran Med, 10(2): 152-6. [Abstract] [Full-text]
12. Diffusion tensor imaging of post mortem multiple sclerosis brain.
    Neuroimage, 35(2): 467-77. [Abstract] [Full-text]
13. CSF enrichment of highly differentiated CD8+ T cells in early multiple sclerosis.
    Clin Immunol, 123(1): 105-13. [Abstract] [Full-text]
14. Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.
    Neurology, 68(12): 939-44. [Abstract] [Full-text]
15. Interferon-beta1a for the treatment of multiple sclerosis.
    Expert Opin Biol Ther, 7(4): 535-42. [Abstract] [Full-text]
16. COX-2 promoter region polymorphisms in multiple sclerosis: lack of association of -765G>C with disease risk.
    Int J Immunogenet, 34(2): 71-4. [Abstract] [Full-text]
17. Multiple sclerosis in Latter Day Saints (Mormons).
    Acta Neurol Scand, 115(4): 260-4. [Abstract] [Full-text]
18. Psychometric study of Turkish version of Fatigue Impact Scale in multiple sclerosis patients.
    J Neurol Sci, 255(1): 64-8. [Abstract] [Full-text]
19. Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial.
    J Neurol Sci, 255(1): 57-63. [Abstract] [Full-text]
20. Progression in multiple sclerosis: further evidence of an age dependent process.
    J Neurol Sci, 255(1): 35-41. [Abstract] [Full-text]
21. Identification of molecular biomarkers for multiple sclerosis.
    J Mol Diagn, 9(2): 197-204. [Abstract] [Full-text]
22. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta.
    J Immunol Methods, 321(1): 19-31. [Abstract] [Full-text]
23. The effect of interferon-beta1a on relapses and progression of disability in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis.
    Clin Neurol Neurosurg, 109(4): 344-9. [Abstract] [Full-text]
24. Fabry disease mimicking multiple sclerosis.
    Clin Neurol Neurosurg, 109(4): 361-3. [Abstract] [Full-text]
25. Myelin transcription factor 1 (Myt1) expression in demyelinated lesions of rodent and human CNS.
    Glia, 55(7): 687-97. [Abstract] [Full-text]
26. Oxidized phosphatidylcholine is a marker for neuroinflammation in multiple sclerosis brain.
    J Neurosci Res, 85(5): 977-84. [Abstract] [Full-text]
27. Repetitive transcranial magnetic stimulation of the motor cortex ameliorates spasticity in multiple sclerosis.
    Neurology, 68(13): 1045-50. [Abstract] [Full-text]
28. Reactivation of JC virus and development of PML in patients with multiple sclerosis.
    Neurology, 68(13): 985-90. [Abstract] [Full-text]
29. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Neurology, 68(13): 977-84. [Abstract] [Full-text]
30. Low frequency of the disease-associated DRB1*15-DQB1*06 haplotype may contribute to the low prevalence of multiple sclerosis in Sami.
    Tissue Antigens, 69(4): 299-304. [Abstract] [Full-text]
31. Clinical and demographical characteristics of primary progressive multiple sclerosis in Isfahan, Iran.
    Eur J Neurol, 14(4): 403-7. [Abstract] [Full-text]
32. Inflammatory cell migration into the central nervous system: a few new twists on an old tale.
    Brain Pathol, 17(2): 243-50. [Abstract] [Full-text]
33. Sodium channels and multiple sclerosis: roles in symptom production, damage and therapy.
    Brain Pathol, 17(2): 230-42. [Abstract] [Full-text]
34. Effectors of demyelination and remyelination in the CNS: implications for multiple sclerosis.
    Brain Pathol, 17(2): 219-29. [Abstract] [Full-text]
35. The immunopathology of multiple sclerosis: an overview.
    Brain Pathol, 17(2): 210-8. [Abstract] [Full-text]
36. Extensive cortical remyelination in patients with chronic multiple sclerosis.
    Brain Pathol, 17(2): 129-38. [Abstract] [Full-text]

© 2004-2012 Multiple Sclerosis Research Today. All Rights Reserved.